Aibin B. Liang

1239 Siping Road
Shanghai, 200092, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 121 publications

Efficacy and safety analysis of the salvage treatment for diffuse large B-cell lymphoma after the failure of anti-CD19 CAR-T therapy

Efficacy and safety analysis of the salvage treatment for diffuse large B-cell lymphoma after the failure of anti-CD19 CAR-T therapy

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study.

Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study.

Journal: Frontiers in oncology

Published: May 20, 2026

Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model.

Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model.

Journal: Frontiers in immunology

Published: April 23, 2026

Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL.

Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL.

Journal: Experimental hematology & oncology

Published: April 03, 2026

Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study.

Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study.

Journal: Frontiers in immunology

Published: February 07, 2026

TRIM37-Mediated Ubiquitination and Degradation of KMT2D Activates JAK2-STAT3 Signaling to Promote Diffuse Large B-Cell Lymphoma Progression.

TRIM37-Mediated Ubiquitination and Degradation of KMT2D Activates JAK2-STAT3 Signaling to Promote Diffuse Large B-Cell Lymphoma Progression.

Journal: Hematological oncology

Published: November 21, 2025

The predictive value of interleukin-2 receptor and prognostic nutritional index in patients with diffuse large B-cell lymphoma.

The predictive value of interleukin-2 receptor and prognostic nutritional index in patients with diffuse large B-cell lymphoma.

Journal: Frontiers in medicine

Published: November 02, 2025

The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma.

The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma.

Journal: iScience

Published: October 09, 2025

Spatially concentrated adenine base editors efficiently correct PLP1 mutations in oligodendrocytes.

Spatially concentrated adenine base editors efficiently correct PLP1 mutations in oligodendrocytes.

Journal: Nucleic acids research

Published: September 29, 2025

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

Journal: American journal of hematology

Published: September 17, 2025

Function-driven design of a surrogate interleukin-2 receptor ligand.

Function-driven design of a surrogate interleukin-2 receptor ligand.

Journal: FEBS letters

Published: September 01, 2025

CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.

CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.

Journal: Journal for immunotherapy of cancer

Published: August 22, 2025

Showing 1-12 of 121

Last Updated: 09/26/2026